



Cite this: *J. Mater. Chem. B*, 2021,
9, 8157

SARS-CoV-2 and approaches for a testing and diagnostic strategy

Delyan R. Hristov,^a Jose Gomez-Marquez,^b Djibril Wade^{ib} ^c and
Kimberly Hamad-Schifferli^{ib} *^{ad}

The COVID-19 pandemic has led to an unprecedented global health challenge, creating sudden, massive demands for diagnostic testing, treatment, therapies, and vaccines. In particular, the development of diagnostic assays for SARS-CoV-2 has been pursued as they are needed for quarantine, disease surveillance, and patient treatment. One of the major lessons the pandemic highlighted was the need for fast, cheap, scalable and reliable diagnostic methods, such as paper-based assays. Furthermore, it has previously been suggested that paper-based tests may be more suitable for settings with lower resource availability and may help alleviate some supply chain challenges which arose during the COVID-19 pandemic. Therefore, we explore how such devices may fit in a comprehensive diagnostic strategy and how some of the challenges to the technology, e.g. low sensitivity, may be addressed. We discuss the properties of the SARS-CoV-2 virus itself, the COVID-19 disease pathway, and the immune response. We then describe the different diagnostic strategies that have been pursued, focusing on molecular strategies for viral genetic material, antigen tests, and serological assays, and innovations for improving the diagnostic sensitivity and capabilities. Finally, we discuss pressing issues for the future, and what needs to be addressed for the ongoing pandemic and future outbreaks.

Received 27th March 2021,
Accepted 15th July 2021

DOI: 10.1039/d1tb00674f

rsc.li/materials-b

^a Department of Engineering, University of Massachusetts Boston, Boston, MA, USA.
E-mail: kim.hamad@umb.edu

^b Little Devices Lab, Massachusetts Institute of Technology, Cambridge, MA, USA

^c iLEAD (Innovation in Laboratory Engineered Accelerated Diagnostics), Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formations (IRESSEF), Dakar, Senegal

^d School for the Environment, University of Massachusetts Boston, Boston, MA, USA

I. Background on SARS-CoV-2 and COVID-19

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, originated in China's Wuhan province in December of 2019, has become an unprecedented worldwide emergency. Its prominence,



Delyan R. Hristov

Delyan R. Hristov is a postdoc in the Engineering Department at University of Massachusetts Boston. He obtained his BSc from Sofia University in 2011 and PhD from University College Dublin (UCD) in 2015. After that, he served as a postdoc at the UCD School of Chemistry and School of Veterinary Science. He joined the group of Hamad-Schifferli in 2018.



Jose Gomez-Marquez

Jose Gomez-Marquez leads the Little Devices Lab at MIT. The group aims to lower barriers to medical prototyping by bringing the worlds of health and manufacturing together. He is a co-inventor of the Ampli and MEDiKit platform, a series of design building blocks that empower doctors and nurses around the world to invent their own medical technologies. Gomez-Marquez has served the European Union's Science Against Poverty Taskforce and has participated as an expert advisor in the President Barack Obama's Council for Advisors on Science & Technology.

rate of infection and potentially fatal outcomes have led to a number of measures including bans on large public gatherings and the close of many businesses. The personal and economic toll of the pandemic has led to an uncertain path forward. One of the major challenges of this crisis has been developing reliable and affordable testing at a scale available to the public.

Clinical diagnosis of COVID-19 is not straightforward as many of the clinical symptoms are relatively common, *e.g.*, cough, fever, and sore throat, which are similar to other respiratory infections. This complicates the identification of COVID and also leads to misdiagnosis of other similar diseases.^{5–8} Beyond the relatively common and variable symptomatology patients may also have a viral or bacterial co-infection which could result in both, abnormal disease patterns and worse outcomes.^{9–11} Therefore, diagnostics tools are often used as confirmation. Computerized tomography (CT) scans are a widely available and commonly implemented non-molecular diagnostics tool. About 85% of symptomatic and 50% of non-symptomatic COVID-19 patients exhibit “ground-glass” opacities apparent in a CT scan.^{12–14}

Innovations in materials science has led to novel strategies for diagnostics, particularly for paper-based systems that utilize nanoparticles for the readout. In the first part of this review, we describe what is presently known about the SARS-CoV-2 virus, its life cycle and infection pathways, and identify the similarities and differences to other coronaviruses in terms of structure, symptomology and clinical diagnosis. In the second part, we discuss the rapid and lab-based detection methods for SARS-CoV-2. In the third part, we discuss the pressing future issues in the context of present day knowledge.

A. Details on coronaviruses

Virus classification. Virus structure and classification are crucial for developing a mitigation strategy in the case of outbreaks. The classification of RNA viruses considers genetic

variability, which often results in viruses with similar genome sequences being classified as variants or strains of the same virus. A metaphor to explain this is different people may be classified as members of an identifiable group. The distinction between members of the same viral species and similar species is the degree of RNA variability. Once the virus species is identified, it is named to identify its proximity to other prominent members of the same viral family.

The full taxonomy of SARS-CoV-2 is: Riboviria > Orthornavirae > Pisuviricota > Pisoniviricetes > Nidovirales > Cornidovirineae > Coronaviridae > Orthocoronavirinae > Betacoronavirus > Sarbecovirus > Severe acute respiratory syndrome-related coronavirus. SARS-CoV-2 belongs to the coronavirus family, is a beta coronavirus, and is classified as SARS-related coronavirus (NCBI taxonomy browser, ID 2697049).

Coronaviruses are enveloped with crown like particles (hence the name) with an average diameter of 80–120 nm. Spike proteins protrude from their surface (Fig. 1a). They have single-stranded, positive-sense RNA (+ssRNA) genomes of approximately 26–32 kb.^{1,16} There exists both a group and subgroup classification system, 1a and b, 2a–d, *etc.* Each group is designated using a Greek letter, *i.e.* alpha coronaviruses (α CoV), beta coronaviruses (β CoV), gamma coronaviruses (γ CoV), and delta coronaviruses (δ CoV).

There are presently seven identified human coronaviruses (Fig. 1b). The first isolated member of the human coronavirus family is HCoV-OC43 (β CoV), which was isolated in 1967. Coronaviruses were largely considered non-lethal until the 2002/2003 SARS-CoV (β CoV) epidemic which resulted in 8273 confirmed cases and 776 deaths (9.6% fatality).¹⁷ Three more human coronaviruses, HCoV-NL63 (α CoV),¹⁸ CoV-HKU1 (β CoV),¹⁹ and MERS-CoV (β CoV) in 2012,²⁰ were identified in the next decade. SARS-CoV-2 emerged in December of 2019 and resulted in the COVID-19 global pandemic.² Presently, there are no identified human γ CoV or δ CoV.



Djibril Wade

Djibril Wade successfully completed his PhD in Biomedical Sciences from the University of Antwerp, Belgium, in 2015 on the implementation of a National CD4 quality control program and decentralization of CD4 monitoring for PLHIV in Senegal. He is a research scientist working at RARS-IRESEF and in 2018 was a visiting researcher at Boston University. Since 2017, Djibril works as a project manager of

iLEAD, collaborating with IVD companies and scientists on innovations with potential to improve laboratory value chains. He has authored 16 publications in international peer-reviewed journals, and was selected as an Africa Rising Star by the African Academy of Sciences and the BMGF in 2019.



Kimberly Hamad-Schifferli

Kimberly Hamad-Schifferli is an Associate Professor in the Engineering Department and the School for the Environment at the University of Massachusetts Boston. She obtained her SB from MIT in 1994 and PhD from the University of California at Berkeley in 2000, and was a postdoctoral associate at the MIT Media Lab. She was a faculty member in the Departments of Mechanical Engineering and Biological Engineering from 2002 to 2012.



Fig. 1 (a) Structure of coronaviruses (Wikipedia), (b) phylogenetic tree of coronaviruses¹ and (c) TEM of SARS-CoV-2.²

Of the seven human coronaviruses presently known, HCoV-OC43, 229E, NL63 and HKU1 are nonlethal and mainly cause seasonal acute respiratory tract infections (ARIs).^{21–24} These viruses often circulate in the same population in colder months and account for ~10% of hospitalizations for ARIs.^{25,26} On rare occasions (~1%), co-infection with more than one coronavirus has been observed, but co-infection with other respiratory viruses is more common.^{21,26} These four coronaviruses are occasionally detected in patients with no symptoms used as a control group.^{18,21} Long term studies at various locations suggest there are no prevalent virus species. Instead, infections vary based on the location and by year. Reports suggest a biannual prevalence cycle which may be due to a level of transitory immunity developed in the population. Furthermore, studies have suggested that there may be some cross-reactive immunity which protects populations from getting infected with viruses from similar species, *e.g.* a HCoV-OC43 outbreak may prevent a CoV-HKU1 outbreak.^{22,23,26} However, other studies found no evidence of cross-immunity.²⁷

MERS-HCoV, SARS-CoV, and SARS-CoV-2 are considered to be lethal coronaviruses all of which are notably β CoV. Of these, MERS-HCoV has the highest reported fatality rate and the lowest infectious rate. According to the WHO, there have been a total of 2519 cases of laboratory confirmed MERS-CoV infections, including 866 associated deaths, and a fatality rate of 34%,²⁸ which have occurred as smaller outbreaks distributed around the world.^{29,30} SARS-CoV is more infectious, but less lethal. There were over 8000 cases of confirmed SARS infection during the 2002 and 2003 outbreak with a fatality rate of ~9.6%.^{31,32} Comparatively, SARS-CoV-2 has the lowest fatality rate, but is much more contagious.³³ Confirmed cumulative COVID-19 cases in the first trimesters of 2020 were ~770 000, which had risen to ~33 500 000 by the end of September and ~83 500 000 by the end of December of the same year, according to WHO data. The deaths in the same period were ~40 000, 1 000 000, and 1 819 000, respectively. The overall fatality rate of the COVID-19 pandemic as of December 2020 is ~2.2%. According to data from the US CDC, the mortality of males over

Table 1 Breakdown of COVID-19 infection and death rate in the US as of 10.10.2020. All numbers are in thousands of cases. *C is the number of cases and D is the number of deaths as reported by the CDC COVID Data Tracker.^{3,4} Population data obtained from Statista.com¹⁵

Age group	Population statistics			COVID-19 case statistics						COVID-19 death statistics					
	Male ($\times 10^3$)	Female ($\times 10^3$)	Total ($\times 10^3$)	Male ($\times 10^3$)		Female ($\times 10^3$)		Total ($\times 10^3$)		Male ($\times 10^3$)		Female ($\times 10^3$)		Total ($\times 10^3$)	
				C*	%	C*	%	C*	%	D*	%	D*	%	D*	%
0–4	10 010	9570	19 580	52	0.5	49	0.5	102	0.5	0.02	0.03	0.02	0.04	0.04	0.04
5–17	31 693	30 360	62 053	185	0.6	189	0.6	374	0.6	0.04	0.02	0.03	0.01	0.06	0.02
18–29	23 060	22 070	45 130	615	2.7	682	3.1	1297	2.9	0.53	0.09	0.28	0.04	0.81	0.06
30–39	22 230	21 930	44 160	450	2.0	459	2.1	909	2.1	1.40	0.31	0.63	0.14	2.03	0.22
40–49	20 000	20 320	40 320	406	2.0	427	2.1	833	2.1	3.39	0.84	1.51	0.35	4.89	0.59
50–64	30 590	32 330	62 920	554	1.8	567	1.8	1122	1.8	15.69	2.83	8.08	1.42	23.77	2.12
65–74	14 700	16 790	31 490	208	1.4	204	1.2	412	1.3	19.68	9.47	12.47	6.10	32.15	7.80
75–84	7000	8970	15 970	107	1.5	127	1.4	234	1.5	22.24	20.78	18.13	14.25	40.37	17.23
85+	2380	4230	6610	57	2.4	115	2.7	173	2.6	19.33	33.75	28.99	25.16	48.33	28.01

18 years of age is twice that of females (Table 1).^{3,4} Similar patterns have been observed in other countries.^{34,35}

Coronavirus structure and infection pathway. SARS-CoV-2 and SARS-CoV are the closest human coronaviruses with a ~93% sequence similarity between their envelope (E), membrane (M), and nucleocapsid (N). Notably, their spike proteins, which mediate the cellular uptake, have a ~82% structural similarity, which decreases to 73% for the receptor binding domain (RBD).³⁶ Of these proteins, N and S are most commonly used for detection and treatment.

The N protein is located within the SARS-CoV-2 virion and is responsible for modulating its structure, replication, and transcription. The protein is mostly expressed during the acute phase of the disease and is abundant in the cell cytoplasm.^{37–39} N protein is of interest because it induces an immune response in the host faster than the S protein.^{39–41}

S proteins are responsible for the cell recognition and entry. S consist of two subunits, where S1 is external to the envelope and contains the RBD, and S2 is in the envelope. The S protein of SARS-CoV-2 is one of the most prominent evolution sites.^{36,42} It has been shown that viral uptake into cells is strongly dependent on the spike structure.^{42,43} The number of reported naturally occurring S variants was 329 as of May 2020.⁴² A classification analysis shows the emergence of viral clusters (or lineages) which may have variant infectiousness and lead to different disease severity.^{44,45} The evolution of SARS-CoV-2 is partially understood. The D614G clade, which was dominant in the second half of 2020, has been shown to be more infectious.^{46–51} The defining mutation of D614G is a substitution at position 614 where an aspartate (D) is replaced by glycine (G) compared to the Wuhan reference strain, and this mutation is often accompanied by several others. Cross immunity between viral strains also is not well understood. There have been several reported cases of SARS-CoV-2 re-infection which can be attributed to different strains.^{52–57} A large-scale study (63 444 patients) of recurrent positive tests showed that ~0.01% of patients had prolonged viral shedding periods (>42 days) which could be explained by reinfection.⁵⁸ Since then more infectious clades have been isolated in various countries.⁵⁹

There are three receptor-mediated cellular uptake mechanisms which have been proposed in the literature, through the angiotensin-converting enzyme 2 (ACE2), CD147, and CD26

(DPP4) receptors. The ACE2 mechanism, also exploited by SARS-CoV and HCoV-NL63,^{60–64} is most commonly cited and considered to be the most prevalent cellular uptake mechanism.^{65–69} The higher infectious rate of SARS-CoV-2 as compared to that of SARS-CoV has been attributed to the higher spike protein affinity for the ACE2 receptor, 4.7 nM for SARS-CoV-2 compared with 31 nM, for SARS-CoV from SPR. Other reports suggest a SARS-CoV-2 affinity of ~15 nM.^{56,67,70,71} The viral cellular uptake is complex and involves several steps. After ACE2 binding the S1 protein has to be cleaved from the viral capsid by the TMPRSS2 protease, or potentially CatB/L to enable cell entry.⁶⁵ SLC6A19 (BOAT1), a neutral amino acid transporter, has been reported to prevent viral entry by preventing S1 cleavage.⁶⁶ Some have suggested that changes in the ACE2 structure could impact the virus binding and thus patient outcomes.⁷²

The CD147 and CD26 receptor dependent uptake pathways have not been investigated to the same degree as that of ACE2.^{73,74} As of writing this article there is little data on the mechanism of interactions between SARS-CoV-2 S and either of the two receptors. Parallels are suggested between SARS-CoV-2, SARS-CoV, HIV, and other viruses binding to CD147 which involves peptidylprolyl isomerase A (PPIA).^{75,76} How SARS-CoV-2 interacts with the immune system, its manifestation as clinical symptoms such as inflammation,⁷⁷ reported drug successes^{74,76,78} and the prevalence of some co-morbidities^{75,79} may be explained by the entry through the CD147 pathway. However, infection through the CD147 pathway is disputed.⁸⁰ There is little mechanistic data on the CD26 receptor pathway, which is more commonly associated with MERS-CoV.^{81–83}

B. Infection route and disease propagation

Virus incubation occurs between 1 and 14 days after infection, during which time the person is still able to infect others.⁸⁴ At present, data suggest that the main infection route of SARS-CoV-2 is through inhalation of large, infected saliva droplets typically present within 2 m of the point of generation.^{84–86} Transmission through smaller droplets which can stay suspended in air is considered to be limited.^{85,87} This is largely based on the relatively low viral reproductive number ($R_0 < 18$), effectiveness of non-medical masks, and transmission mechanism of SARS-CoV.^{85,86,88} Some reports have attempted to develop spread

models through saliva droplet mechanics. Stadnytskyi *et al.* calculated the probability of a virus particle being present in droplets of various sizes as 37%, 0.37%, and 0.01% for a 50, 10, and 3 μm , respectively, and the effect of evaporation on transmission.⁸⁹ Others have discussed the effect of droplet size, shape, and chemical makeup on infectious rates.^{87,90–92} Interestingly, it was observed that some people may act as super spreaders due to their droplet generation patterns.^{90,93}

Though airborne transmission is considered rare, it has been reported that it is more likely in enclosed spaces with poor ventilation or in locations where a large number of sick individuals congregate.^{85,90,94–96} A high concentration or abnormal droplet properties can lead to virus accumulating in the environment over time.^{89,92} Inappropriate ventilation can lead to larger particles being spread beyond the 2 m diameter.^{87,90} These concerns may be especially relevant in hospital settings. Some reports suggest that asymptomatic patients are less contagious, possibly due to lower droplet generation.^{97,98} Conversely activities generating a lot of droplets, such as singing, may increase the infection rate.⁹¹ On a molecular level the inhalation pathway is interesting due to the relatively high expression of ACE2 and TMPSS2 in the oral and nasal cavity, and respiratory system together with low expression of SLC6A19.^{99,100}

C. SARS-CoV-2 immune response and duration

Understanding the timing and duration of seroconversion is crucial for diagnostics as the target of interest changes with the immune response. The immune response is a complex process which involves activation of several systems. These include the synthesis of inflammatory cytokines, innate and at a later stage the adaptive immune system.^{42,101–103} Most viruses, including SARS-CoV-2 interact with the immune system to subvert or suppress it.^{104–107}

Most studies report seroconversion rates within two weeks of infection (Fig. 2).^{108–113} Interestingly, in at least one study, IgM generation had a similar rate to that of IgG and not all patients developed an IgM response.¹⁰⁸ Both antibody generation and prevalence time in serum were reported to scale with disease severity.^{42,110} Asymptomatic and mild cases had low antibody generation and prevalence similar to that of non-lethal

coronaviruses,^{114,115} while more severe cases had a more pronounced immune response for longer times, similar to other lethal coronaviruses.^{115–117} Though cross-immunity with other viruses is not well understood, emerging studies suggest some individuals may have some degree of pre-existing immune response.^{118,119}

There is little data on the persistence of generated antibodies. In a notable report, Prevost *et al.* observed a 26% decrease in antibody concentration in patient serum within the three month study period in a large cohort of 365 000.¹⁰⁹ IgG prevalence changed from 6% in June/July to 4.4% in late September. Importantly, antibody prevalence was established *via* a self-administered lateral flow immunoassay (LFA),¹²⁰ thus there could be some thresholding limitations. Iyer *et al.* reported a median seroreversion time, *i.e.* the time taken to lose antibody seroprevalence, of 49, 71, and 90 days for IgM, IgA, and IgG, respectively.¹²¹ Other studies report antibody decrease in a similar timeframe.^{122,123} In contrast, other reports find little change in the IgG seroprevalence over a three-month period.^{124–126} Such inconsistencies could be attributed to the differences in antibody measurement methods used, cohort size and demographics, and infection severity. More recently, longer-term studies have suggested that 95% of individuals have a sustained immune response for 5 to 8 months post-symptom onset.¹²⁷

A short and/or low persistence, or poor cross-species immunity of the SARS-CoV-2 response could lead to re-infection and account for the 3 to 61% patient re-admission rates into hospitals following discharge.^{128–131} Though these mechanisms are poorly understood for COVID-19, they have been proposed for non-lethal coronaviruses.^{114,130,132–134} Hospital re-admission could also be due to false negatives, the use of different diagnostics tools, and the lack of guidelines standardization in the field.^{104,128,135}

D. SARS-CoV-2 vaccine development and impact on antigen diagnostics

Vaccine development has been seen as a sustainable solution to the COVID-19 pandemic and started in the first trimester of 2020.^{136,137} The number of vaccine candidates in the production pipeline has increased from ~ 78 before May 2020¹³⁸ to 158–166 in September/October 2020.^{139–141} As of February 2021, there are at least seven different vaccines that have been administered to more than 175 million people worldwide.^{137,142} Two have been approved by select countries.¹³⁷ Pfizer and Moderna candidates, both of which are mRNA vaccines, have reported a 90% and 95.4% efficiency, respectively, and were approved in December 2020 with others to follow.^{143–146}

Widespread vaccination would impact the applicability of antibody and seroconversion studies for disease detection which are more likely to be used to monitor the vaccine efficiency and seroreversion rate.

II. Approaches for COVID-19 diagnostics

Molecular diagnostics developed for SARS-CoV-2 detection are RT-PCR, ELISA, and rapid paper-based among others. Industry




Fig. 2 Infection time course for COVID-19 and symptom onset. Diagnostic test assay at each stage for different biomarkers from the virus.

has led the way in innovative approaches, accelerated by mechanisms for emergency approval and increased funding for commercial systems.^{147–149} Considerations for COVID-19 testing include technical factors, such as diagnostic sensitivity and specificity, and also availability, cost, turnaround time, and the end user who performs the assay.^{150,151} Because of the massive demand for tests, a range of different test types are necessary to be able to continually meet the demand. We compare diagnostic approaches and materials innovations that can potentially improve them. Because of the format, the majority of materials and chemistry advancements have been primarily focused in the lateral flow assay formats.

A. Nucleic acid diagnostic tests

The most common diagnostic approach is the reverse transcription polymerase chain reaction (RT-PCR), or quantitative RT-PCR (qRT-PCR), both of which detect the presence of the viral genetic material present upon infection, and which persists up to a couple of weeks post-infection (Fig. 2).

Viral RNA is detected by first reverse transcribing it into DNA, which is then enzymatically amplified until it reaches a detectable level. The presence of the DNA is optically read out using fluorophore–quencher probes specific to the DNA sequences of interest. PCR results are often described in terms of the cycle threshold (C_t), *i.e.* the number of replication cycles before a detectable fluorescence signal appears.^{152,153} Commercial diagnostics typically test for the presence of a specific SARS-CoV-2 gene set. These are usually the ORF1b and ORF8 genes, with sometimes including the S, N or E genes. The patient sample for PCR is usually a nasopharyngeal (NP) swab and thus requires an initial extraction step to isolate the nucleic acid from the sample matrix.

PCR has high sensitivity and can detect trace amounts of target, and so it has the potential to detect an infection at an early stage before the immune response and the patient exhibits symptoms. The lowest LODs observed have been 9 copies per mL from PerkinElmer with a low false positive rate.¹⁵⁴ Furthermore, due to the specificity of the nucleic acids, RT-PCR can differentiate between species of coronaviruses as well as clades within species.^{21,26,52–57} Furthermore, the methodology can be used on a wide variety of samples and can yield information on patient viral shedding and infectiousness.^{155–157} Due to the rapid turnaround times on sequencing and the sharing of genetic codes, the scientific community was able to rapidly develop a RT-PCR diagnostic and several commercial tests were approved early in the pandemic. Many institutions have established guidelines for patient diagnosis by PCR as the gold standard.¹⁵⁸

There are several drawbacks to RT-PCR, mostly in field detection. The procedure must be done in a centralized lab location, using various reagents (*e.g.* primers) and instruments operated by trained technicians. Because of this, it requires relatively high resources to run the tests, and beyond the abovementioned personnel and lab equipment, this includes sample transport and cold chains for reagents. A single test can require several hours, where the time from obtaining a sample to receiving a result can be days depending on the laboratory

load. Though RT-PCR can be used for multiplexed testing, clade testing complex multiplexing procedures could cost more than \$3000,¹⁵⁹ which makes them impractical for widespread use. Laboratory setup required for a new facility can cost more than \$15 000.^{160,161} Setting up and running diagnostic labs can be costly and time consuming, making scale-up difficult, especially if it is only needed temporarily.

Supply chain logistics can also be a limiting factor, and diagnostic testing was held up at stages of the pandemic due to shortages of necessary components, such as the DNA extraction kits and swabs for taking samples. Low resource areas or those with a modest population density may not have local testing facilities and thus samples would need to be shipped adding time to diagnosis.

Point-of-care tests: nucleic acid. Because of the shortcomings of lab-based PCR, alternatives that are amenable to point-of-care use have been explored.

Isothermal amplification techniques. Isothermal amplification lends itself well to a point-of-care format as it requires fewer reagents and simplifies the instrumentation requirements. Isothermal techniques can amplify the nucleic acids at a fixed temperature, and thus does not require thermal cycling. This removes the need for instrumentation that can dynamically control the temperature of the reaction. There are now several isothermal amplification techniques available. The most widely used technique is loop mediated isothermal amplification (LAMP), which relies on a strand displacement mechanism.¹⁶² Amplification and detection are done simultaneously in a single tube, and thus LAMP can achieve results more quickly than traditional PCR. Furthermore, the reaction is more robust with respect to pH and temperature. Consequently, LAMP can be adapted to novel formats, such as bead-based readouts, nanoparticle labels, nanopores, microfluidic devices, and others.¹⁶³

RT-LAMP has been developed successfully for SARS-CoV-2 diagnostics. While not as sensitive as RT-qPCR, it is significantly simpler to carry out, and the RNA isolation step can even be removed.¹⁶⁴ The first FDA approved at-home COVID test in the US was an RT-LAMP system from Lucira. The test is fully self-contained and simple to use, and the system includes an instrument for readout. The Lucira tests can be carried out with the result in 30 min, with an estimated cost of ~\$50.¹⁶⁵

Nucleic acid tests on paper substrates. Many point-of-care tests use paper as a substrate, which can serve as a robust medium for the reaction and also be used for sample separation and purification. Paper is of low-cost and can be manufactured on a large scale.¹⁶⁶ Efforts to use paper substrates for nucleic acid tests have been accelerated by developments using CRISPR (clustered regularly interspaced short palindromic repeats).¹⁶⁷ While the CRISPR RNA-guided endonuclease-based nucleic acid editing tool has been pursued for various applications, it has also been adapted for use as a molecular diagnostic.¹⁶⁸ Specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) has been commercialized (Mammoth) for SARS-CoV-2 detection. The nucleic acid in a sample is isothermally amplified and then incubated with

Cas13-crRNA and reporter RNA that has a fluorophore-quencher pair. If the target is present, the reporter RNA is cleaved, unquenching the fluorophore. The format is on a paper immunochromatographic strip for fluorescence readout of the probe strand at the test line. It exhibits sensitivity and specificity comparable to that of traditional PCR, with detection limits of 1–10 copies per μL or 2 aM of DNA/RNA.^{169,170} SHERLOCK for CRISPR obtained an FDA emergency use authorization (EUA). Similar approaches using CRISPR have been explored such as DNA endonuclease-targeted CRISPR trans-reporter (DETECTR).

Direct detection of nucleic acids with novel biosensors. In addition, routes to directly detect viral nucleic acids without amplification or reverse transcription have been pursued. Direct detection removes the need for steps associated with amplification, and have the potential to minimize contamination issues. For example, nucleic acids can be detected electrochemically with improved sensitivity through the use of developed labels and/or probes.¹⁷¹ Zhao *et al.* employed a “supersandwich” where the probe that can hybridize to the target is a gold and iron oxide nanoparticle complex, and the electrode with the capture probe strand is a *p*-sulfocalix[8]arene (SCX8) – functionalized graphene oxide. The calixarene serves to enhance the electrochemical signal. By doing so they were able to achieve ultrasensitive detection, with a limit of detection (LOD) of 200 copies per mL in clinical specimens. Furthermore, they were able to adapt the electrode into a portable system that could be readout with a smartphone.¹⁷²

The plasmonic response of devices can be used to detect SARS-CoV-2.¹⁷³ Qiu *et al.* explored a combination of plasmonic sensors with photothermal heating to directly detect SARS-CoV-2 nucleic acids.¹⁷⁴ The authors conjugated thiolated DNA strands to the two-dimensional gold nanoislands to enable the detection of a target RNA. Successful binding was indicated by a change in the localized surface plasmon resonance response (LSPR). They were able to generate a secondary signal by strand dehybridization caused by heat generated by illuminating the LSPR. Non-matching pairs were displaced with a higher dissociation rate constant than complementary strands, hence improving the sensor discriminatory performance. Using a combined dual mode sensor can lead to achieving an LOD down to 0.22 pM.

B. Paper-based rapid immunoassays for antigens

Other diagnostics test for the presence of viral antigens, *i.e.* proteins that are produced by cells in response to the infection, or proteins composing the virus itself. SARS-CoV-2 infection does not result in the secretion of specific antigens at high concentrations, so the target antigens are the viral proteins.

Lateral flow immunoassays (LFA) have been used as the format for point-of-care diagnostics for a wide range of diseases.¹⁷⁵ Assays consists of a sample pad, conjugate pad, test strip, and wick (Fig. 3a). Briefly, the biofluid is added to the strip and migrates towards the absorbent pad by capillary action. The biomarker binds to antibodies conjugated to gold nanoparticles that are dried down in the conjugate pad. The biomarker–nanoparticle–antibody conjugate then migrates




Fig. 3 Lateral flow immunoassays (LFAs). The patient sample, containing the antigen, is added to the sample pad and wicks through the strip. Nanoparticle–antibody conjugates dried in the conjugate pad bind to the antigen, and the complex is captured at the test line to form a sandwich immunoassay. The control line has immobilized antibodies that bind to the nanoparticle–antibody conjugate itself. A positive test is indicated by color appearing at both the test (T) and control (C) lines. A negative test results in color only at the control line.

through the strip and binds to immobilized capture antibodies at the test line (Fig. 3b). This double binding event, where the antigen binds to both the immobilized antibodies and the antibody on the nanoparticle, is called a “sandwich immunoassay” and results in a visible color at the test line due to the presence of the gold nanoparticles, which have a strong color due to their surface plasmon resonance (SPR) (Fig. 3).^{176–178}

LFAs are attractive due to their ease of use, ease of operation by non-experts, and their short response times, which can be minutes instead of hours or days. The required sample volumes are relatively small (<100 μL). Typically, a biological fluid is added directly to the strip with little or no sample preparation. Manufacturing and scale-up of an off-the-shelf LFA test is relatively easy, resulting in tests that cost as little as a few USD to produce.¹⁷⁹ Many LFAs are stable for long periods of time and do not require special storage conditions,¹⁷⁵ and the majority of them do not need electrical power or external devices for operation. Thus, LFAs are attractive for widespread application. They largely fulfill the WHO ASSURED criteria (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable to end-user) for diagnostics to be used in low resource settings.^{180,181}

There are several commercial SARS-CoV-2 antigen test kits on the market, including those by Quidel, Abbott, Becton Dickinson, and other companies.^{182,183} Many of these go from the sample to produce the result within minutes and are easy to use. However, a trade-off exists between the performance and rapid turnaround times, where antigen tests have lower specificity and sensitivity than nucleic acid based tests. In particular, LFAs

for SARS-CoV-2 have met several challenges as viral infection does not result in secretion of a protein biomarker like nonstructural protein 1 (NS1) for the case of flaviviruses,¹⁸⁴ such as dengue, or glycoprotein (GP) for filoviruses (Ebola).¹⁸⁵ LFAs are relatively easy to multiplex so that they can detect multiple antigens.¹⁸⁶

LFAs require antibodies that bind to the antigens in pairs, and their performance is highly dependent on optimizing the binding affinity of antibodies. Efforts to evaluate the performance of a large number of antibody pairs have helped shorten the test development time and aided in reagent discovery. Cate *et al.* screened 673 different antibodies for the SARS-CoV-2 N protein that can bind to antigens in pairs.¹⁸⁷ They tested combinations of the different antibodies on a high throughput robotic screening platform and identified the pairs that could bind to the viral proteins. Antibodies were ranked quantitatively in signal intensity that they produced in pairs. These kinds of tools to share data helped accelerate the diagnostic discovery process.

LFAs and other paper-based immunoassays have low sensitivity and selectivity compared to PCR, typically in the 10–100 ng mL⁻¹ range.¹⁷⁸ In addition, LFAs can exhibit high variability which leads to low reliability, which was demonstrated during the first wave of the 2020 COVID-19 pandemic where lower regulations for diagnostics led to a number of low performance tests flooding the market.

Innovations in antigen tests. Because of the limited sensitivity of SARS-CoV-2 LFAs, methods to increase their sensitivity have been pursued. Some studies estimate that antigen test sensitivity needs to increase by an order of magnitude.^{186,188} This can be achieved by utilizing a digital reader, which quantifies the test line intensity. Additional strategies can be to implement additional labels which can be read either colorimetrically (Abbott BinaxNOW with Ag CARD), by fluorescence (Quidel, Sofia), *via* a Raman spectrometer, or chemiluminescence through enzymatic amplification.¹⁸⁹

State of the art advancements to antigen LFAs come in many forms. Surface enhanced Raman spectroscopy (SERS) has been applied to LFAs to increase the sensitivity of the signal readout. The Raman spectra of a molecular analyte are often used as a unique identifier, where it serve as a “molecular fingerprint.” Raman spectral intensity is greatly enhanced by several orders of magnitude (10⁹ or greater) when the analyte is in proximity to a roughened or nanoscale noble metal surface. SERS is highly sensitive and has been used to detect analytes down to attomoles, and the dyes do not suffer from photobleaching like with fluorophores. The formats of SERS that have been useful for diagnostics are those that employ a Raman “nanotag,” which is a gold or silver nanoparticle decorated with a Raman reporter and conjugated to the antibodies specific for the target.¹⁹⁰ The presence of the target is detected by recording the Raman spectra of the reporter molecule in the nanotag. This strategy has been used to enhance the sensitivity of paper immunoassays for other diseases in a multiplexed manner, where each nanotag is functionalized with a different Raman reporter, such as for dengue and zika nonstructural protein 1 (NS1).^{191,192}

Another route to increase the sensitivity of LFAs is to use lanthanide-doped nanoparticles, such as Eu doped polystyrene.

Lanthanides possess narrow fluorescence emission lines with long lifetimes and Stokes shifts larger than standard fluorophores. Because of their long fluorescence lifetimes, time-resolved fluorescence can be used to remove the background fluorescence. Readout is achieved with a fluorescent reader equipped for time resolved measurements. Time resolved fluorescence has been used successfully to increase the sensitivity of LFAs for HIV and for prostate specific antigens.^{193,194}

Other efforts have been made using electrochemical sensing elements to increase sensitivity over the traditional paper immunoassays. Seo *et al.* have successfully utilized a graphene based field effect transistor (FET) to detect spike proteins.¹⁹⁵ SARS-CoV-2 spike antibodies were chemically conjugated to a graphene sheet, which is incorporated into the FET. The device results in a change in the electrical response when a spike protein is present. The authors also demonstrated utility in clinical samples, with a LOD of 1 fg mL⁻¹ for the spike protein, and 1.6 × 10¹ pfu mL⁻¹ for the virus.

The phenomenon of gold NP aggregation is often used for biosensing, where the presence of the target is indicated by a color change. Ventura *et al.* used this colorimetric change for detecting SARS-CoV-2 proteins.¹⁹⁶ Gold NPs were conjugated to antibodies for spike, envelope, and membrane proteins. In the presence of virions, the NPs aggregated due to the antibody-antigen binding, resulting in a shift of the SPRs, due to the proximity of the NPs to one another. This can also be detected with the naked eye, as the color of the sample is changed from red to blue. They determined a LOD of a virion concentration corresponding to a threshold count (C_t) = 36.5.

Additional strategies to improve the sensitivity of LFAs included isotachopheresis,¹⁹⁷ photothermal heating,¹⁹⁸ silver staining, and multicolored nanoparticles for multiplexing,¹⁸⁴ all of which can be applied to SARS-CoV-2 LFAs.

C. Serological tests for SARS-CoV-2 antibodies

A viral infection can be detected through the host immune response, specifically through the presence of IgM and IgG antibodies. This strategy, commonly referred to as serological testing, is often used to detect for present or past exposure, seroconversion rate, and sometimes long-term immunity to an infectious disease. IgM is an indicator of an early stage infection, while IgG persists longer (Fig. 2).¹⁹⁹ Whether the presence of these antibodies for SARS-CoV-2 indicates immunity to COVID-19 is still being determined.²⁰⁰ Because of the timing of the seroprevalence windows and the limited sensitivity of the IgG/IgM tests, they are not recommended for disease diagnosis. However, the low production cost, rapid turnaround and mass manufacturing capability make this strategy particularly lucrative to monitor the rate of seroconversion and seroreversion, *i.e.* the loss of antibodies over time, in the population.

ELISA. IgG/IgM assays are traditionally performed using enzyme linked immunosorbent assay (ELISA). ELISA uses a plate reader format and thus is typically performed in a centralized lab location. Usually the antigen such as the SARS-CoV-2 spike protein is immobilized on the plate well, and then the patient sample is added. If antibodies for the

target antigen are present in the sample, (e.g., anti-spike IgG and/or IgM) they will bind to the plate after washing steps. The presence of IgG/IgM is tested *via* a labeled secondary antibody which broadly binds to human IgG or IgM. An example of a typical label is horseradish peroxidase (HRP) which converts a substrate such as 3,3',5,5'-tetramethylbenzidine (TMB) into a colorimetric species and thus produces an optical signal.²⁰¹ Like PCR, ELISA has high sensitivity and selectivity, but these depend on the antibodies used and the protocol. The selectivity and specificity of serology tests are in the 80–100% range.^{202–204} ELISA shares some of the drawbacks of PCR regarding instrumentation and trained personnel which can result in testing bottlenecks.

Serological paper immunoassays. LFAs have been adapted for SARS-CoV-2 IgG/IgM detection. These have been successfully developed for many other diseases, including visually read out tests that use gold nanoparticles.^{34,205} During the pandemic, several commercial COVID-19 antibody tests appeared on the market, but none were sufficient to gain FDA approval. While they were easy to use, many of them suffered from low sensitivity and highly variable results, yielding both false positives and false negatives.^{206,207} Some showed a sensitivity/selectivity as low as 30% in some clinical settings, which increased to >90% after the 14–20 day seroconversion threshold.^{203,206} Due to their lack of specificity and high variability, these were eventually taken off the market.

Serological LFAs can be optimized using the same strategies to enhance antigen LFAs discussed earlier. Liu *et al.*²⁰⁸ used a sandwich immunoassay enhanced with a nanotag. The spike protein was conjugated to SiO₂/Ag core-shell particles that contain the Raman dye 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB). DTNB is a well-characterized Raman-active species with narrow spectral lines. Anti-human IgG and IgM were immobilized on the test lines. This format could enhance the signal to detect IgG and IgM with 800X higher sensitivity compared to a visual readout of AuNPs. While the instrument used is a benchtop system, it could be extended for use with a commercially available handheld Raman spectrometer. By conjugating Eu-doped nanoparticles (LNPs) to anti-IgG for use as the label antibody, with immobilized nucleoprotein on the test line, Chen *et al.* were able to detect anti-nucleocapsid IgG antibodies developed in response to SARS-CoV-2 in confirmed patient samples.²⁰⁹

D. Important factors in LFAs

Recognizing the underlying phenomena occurring in LFAs is key to improving their design and performance. The impacting factors can be grouped into several general categories: (i) physical substrate, (ii) sample type, (iii) chemistry of the immunoprobe used, (iv) its interaction with the media, (v) running conditions and (vi) others. Other factors to consider are the label size vs substrate pore size, substrate cohesion and interaction with the solvent and sample flow rate.^{178,210–212}

Immunoprobe design is multi-layered and can be broken down to (i) nanoparticle materials, (ii) conjugation chemistry, (iii) stabilization chemistry and (iv) targeting agent affinity.

Nanoparticles are mostly used as labels, thus the signal type and strength is considered one of their prime attributes. Gold nanoparticles are commonly used due to their chemical stability, ease of synthesis and functionalization and controllable, visible color.²¹³ However, many other materials have been successfully applied as discussed below. The material properties may often be altered or improved by the addition of tags or secondary labelling agents, for example, the use of SERS tags to lower detection limits.

Stabilization and conjugation chemistry are often related and affect the stability and functionality of the immunoprobes. We have previously discussed this factor to some length.^{177,178,214} Conjugation can be done physiochemically, *i.e.* by adsorption, or by covalent bonds. Polyethylene glycol (PEG) is typically used to stabilize the particles.^{177,215} Furthermore, both conjugation and stabilization chemistries can affect the interaction of the immunoprobe with molecules in the sample, such as other proteins. In turn this could impact the particle behavior in the test.^{177,216}

Matrix effects are challenging for any biological application using nanoparticles, which is no exception for diagnostics.²¹⁷ In paper-based immunoassays nanoparticle aggregation can lead to signal reduction and thus higher test-to-test signal variability. Another often overlooked factor is biomolecular corona formation. This is the adsorption of molecules native in the sample onto the immunoprobe.^{218–220} Coronas can be beneficial for assay performance as they can passivate the nanoparticle and reduce aggregation, but detrimental due to partial screening of immunoprobe functionality leading to a lower signal.

E. Impact of computational methods on paper-based assays

Beyond test development, another strategy to improve LFAs and diagnostic approaches in general is the application of computational and large data modelling methods. Such models have been used to improve the design of nanoparticles and binding strategies used in drug design and diagnostics, paper flow along other aspects of LFAs.²²¹ Computational methods have also been used to improve the sensitivity and selectivity of existing tests by advanced image and data analysis. For example, Rodriguez-Quijada *et al.* were able to develop a relatively simple multiplex test to detect and differentiate Dengue and Zika viruses in samples by using differently colored gold immunoprobes where test results were analysed using machine learning.¹⁸⁴ Finally, big data analysis for enhanced monitoring and containment of the disease has been proposed. The COVID-19 pandemic demonstrated the ability of such platforms to empower scientists, inform legislative decision making and affect public sentiment.²²² An additional area of research which has been gaining interest of late is the internet of medical things (IoMT).²²³ In future this strategy could help improve LFAs and other point-of-care tests by integrating the various levels of the information chain, from clinical validation test to large-scale disease monitoring (Fig. 4).²²⁴




Fig. 4 Innovations in antigen testing to improve the sensitivity of COVID-19 antigen tests.

III. Challenges for COVID-19 diagnostics and future directions

A. Challenges

Despite all of the progress in COVID-19 diagnostic development, many challenges remain (Fig. 5).²²⁵ Despite the fact that LFAs are one of the formats most amenable to POC use, they have not been as widespread in COVID-19 testing as PCR.

First, the sensitivity of COVID-19 POC tests limits their ability as a diagnostic tool. Rapid paper tests have typical LODs of 10–100 ng mL⁻¹, which is sufficient for many other diseases such as dengue and other flaviviruses, where the biomarker of nonstructural protein 1 (NS1) is present in the blood of infected patients at levels of a few orders of magnitude higher than these LODs, and is present within 1–2 days. However, for COVID-19, antigen levels are anticipated to be much lower. Furthermore, the time course of when antigens are present at detectable levels is not as immediate as for flaviviruses, where the long asymptomatic period hinders detection. While there is always a trade-off between sensitivity and portability/ease of use for LFAs, the nature of the viral infection impedes the ability to diagnose *via* antigen detection.




Fig. 5 Continuing challenges and issues for COVID-19 diagnostic strategies.

Another major challenge for COVID-19 POC antigen tests is their poor repeatability, which is somewhat linked to their sensitivity. Some reports have found that the repeatability of antigen tests is nonideal. Recommendations from regulatory agencies early in the pandemic suggested end users to take antigen tests multiple times, especially from different manufacturers. In previous outbreaks of emerging infectious diseases such as Zika and Ebola viruses, antigen test development took 1 year with the development efforts greatly expedited by health and funding agencies. As work continues in diagnostic development, these issues may be addressed with further refinement. This will undoubtedly be bolstered by other efforts in improving the capabilities of antigen tests through materials and sensing innovations.

B. Supply chain logistics

Furthermore, COVID-19 has underscored issues that have not been as prominent for other diseases with smaller disease burdens. For example, the massive demand for diagnostics has led to bottlenecks in the supply chain for the biological reagents and materials and testing personnel. While the innovation cycle was greatly accelerated for COVID-19, with genetic sequences, antibodies, and vaccines developed at a record pace, issues of scalability and global access have hindered efforts to surveil and contain the disease. The vulnerability of supply chains and stockpiling of materials for emergency response were also underlined. Areas with poor infrastructure, both road, and utility, present a further challenge.

C. Capacity building in low and middle income countries

Such issues are expedited in resource limited settings where access to testing facilities or even medical services may be limited.^{150,226,227} Sending self-contained systems are ultimately limited in their efficacy, as they are black boxes that provide only short term solutions. Locations may not have the trained personnel to use such systems or alter them to fit local needs. Stockpiling and supply chain vulnerability are exacerbated in such settings. One possible route is to invest in the development of local expertise and fabrication of reagents and increase engagement with such communities.²²⁸ Innovations for decentralized drug synthesis and diagnostics development can

be applied. This further reinforces the need to invest and develop more tests which adhere to the ASSURED criteria¹⁸¹ to help alleviate scale-up and supply challenges.

Efforts to address these challenges have been in the form of capacity building, especially in low and middle income countries which have had comparatively lower testing rates. The African Union and African CDC formed the Partnership to Accelerate COVID-19 Testing (PACT)²²⁹ with the goal to expand testing throughput to contain transmission.²³⁰ Examples include DiaTropix in Senegal to fabricate low-cost tests, in collaboration with industrial partners and the non-profit Foundation for Innovative New Diagnostics (FIND). Because the diagnostic tools will be locally produced, it avoids issues with external supply chains, and thus can improve accessibility. Furthermore, it can help towards responding to future outbreaks, as the infrastructure for fabricating diagnostic tools will already be in place.²³¹ Finally, capacity-building efforts must ensure that they result in sustainable solutions, accounting for use of local reagents, as well as service and maintenance for equipment. In these settings, big data analysis and IoMT could be especially effective in improving the resource deployment and combating future disease outbreaks.

D. Communication to the public

Another aspect of disease management which should not be overlooked is appropriate communication of information to public facing media and the public directly. While scientific understanding of containment aspects and strategies, such as mask wearing and social distancing, is important, suitable implementation and adherence need also to be considered. Miscommunication is detrimental, where false negative/positive result rates, diagnostic strategies, and the reasoning behind them need to be clearly communicated and explained. Fostering public understanding and trust through clear and transparent communication and policies can help improve the disease burden through higher compliance.

III Conclusions

Perhaps the lessons learned can serve as a silver lining to the COVID-19 pandemic. It has underlined faults and vulnerabilities within the existing healthcare systems, and has highlighted the specific emerging fields.²³² The data and understanding accumulated during the COVID-19 pandemic, if applied well, can not only help reduce the prevalence and spread of other diseases such as influenza but also reduce the impact of future global pandemics.

Fears of zoonotic crossover into humans are not new,²³³ as all three of the lethal coronaviruses have made this transition in the last two decades. Thus, it is unlikely that this pandemic would be the last of its kind. Furthermore, the increase in international travel makes containment by a single country unlikely. The COVID-19 pandemic has taught us that we need to be better prepared for future outbreaks. Improving global

and local testing capacity and improving the scientific, industrial, and manufacturing infrastructure is vital.

It is likely that SARS-CoV-2 will become a continual health concern, even with the deployment of several vaccines.^{234,235} Vaccine access is not universal, so diagnostics are still necessary for diagnosing patients and also disease surveillance. This leads to an unprecedented global need for diagnostics to both monitor the spread of the disease and the seroconversion/seroreversion rate in the population. A sound viral detection strategy is important for containing future outbreaks and managing societal well-being.

Clearly, understanding the viral infectious profile in the host is important for using this information to develop diagnostics and procedure standardization. It would help improve standard procedures and ensure that the appropriate sample is collected depending on patient disease history. Such a strategy could (i) reduce false positive/negative rates, thus improving confidence in results, (ii) ensure infected patients are identified promptly and released when appropriate, thus improving patient outcomes and containing the spread, and (iii) improve disease proliferation monitoring and understanding. Implementing a robust and actionable standardization strategy would help differentiate between an abnormal viral shedding profile and re-infection. In turn, this could help identify and contain new viral strains more rapidly. Ultimately, innovations in new materials for devices, probes, and sensors can aid in meeting the demands of higher sensitivity, lower cost, and robustness and repeatability.^{223,236}

Author contributions

DRH, DW, JGM, and KHS contributed to the writing of this manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors would like to thank for supporting funds from the University of Massachusetts Boston.

Notes and references

- 1 B. Chen, E.-K. Tian, B. He, L. Tian, R. Han, S. Wang, Q. Xiang, S. Zhang, T. El Arnaout and W. Cheng, *Signal Transduction Targeted Ther.*, 2020, 5, 1–16.
- 2 N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi and R. Lu, *N. Engl. J. Med.*, 2020, 727–733.
- 3 *Demographic Trends of COVID-19 cases and deaths in the US reported to CDC*, Centers for Disease Control, 2020.
- 4 Weekly updates by select demographic and geographic characteristics: Provisional death counts for Coronavirus

- Disease 2019 (COVID-19), Centers for Disease Control, 2020.
- 5 G. Yan, C. K. Lee, L. T. Lam, B. Yan, Y. X. Chua, A. Y. Lim, K. F. Phang, G. S. Kew, H. Teng and C. H. Ngai, *Lancet Infect. Dis.*, 2020, **20**, 536.
 - 6 A. Wilder-Smith, H. Tissera, E. E. Ooi, J. Coloma, T. W. Scott and D. J. Gubler, *Am. J. Trop. Med. Hyg.*, 2020, **103**, 570–571.
 - 7 R. Yousefzai and A. Bhimaraj, *JACC: Case Reports*, 2020, 1614–1619.
 - 8 L. Epelboin, R. Blondé, M. Nacher, P. Combe and L. Collet, *J. Trav. Med.*, 2020, **27**, taaa114.
 - 9 J. Stowe, E. Tessier, H. Zhao, R. Guy, B. Muller-Pebody, M. Zambon, N. Andrews, M. Ramsay and J. L. Bernal, *medRxiv*, 2020, DOI: 10.1101/2020.09.18.20189647.
 - 10 D. Kim, J. Quinn, B. Pinsky, N. H. Shah and I. Brown, *JAMA*, 2020, 2085–2086.
 - 11 Y. Kondo, S. Miyazaki, R. Yamashita and T. Ikeda, *BMJ Case Reports CP*, 2020, **13**, e236812.
 - 12 U. Teichgräber, A. Malouhi, M. Ingwersen, R. Neumann, M. Reljic, S. Deinhardt-Emmer, B. Löffler, W. Behringer, J.-C. Lewejohann, A. Stallmach and P. Reuken, *Respir. Res.*, 2021, **22**, 13.
 - 13 T. C. Kwee and R. M. Kwee, *RadioGraphics*, 2020, **40**, 1848–1865.
 - 14 Y. Wang, C. Dong, Y. Hu, C. Li, Q. Ren, X. Zhang, H. Shi and M. Zhou, *Radiology*, 2020, 200843.
 - 15 E. Duffin, Resident population of the United States by sex and age as of July 1, 2019, <https://www.statista.com/statistics/241488/population-of-the-us-by-sex-and-age/>.
 - 16 I. M. Artika, A. K. Dewantari and A. Wiyatno, *Heliyon*, 2020, e04743.
 - 17 Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 World Health Organization, 2004.
 - 18 L. Van Der Hoek, K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. J. Berkhout, K. C. Wolthers, P. M. Wertheim-van Dillen, J. Kaandorp, J. Spaargaren and B. Berkhout, *Nat. Med.*, 2004, **10**, 368–373.
 - 19 P. C. Woo, S. K. Lau, C.-M. Chu, K.-H. Chan, H.-W. Tsoi, Y. Huang, B. H. Wong, R. W. Poon, J. J. Cai and W.-K. Luk, *J. Virol.*, 2005, **79**, 884–895.
 - 20 A. M. Zaki, S. Van Boheemen, T. M. Bestebroer, A. D. Osterhaus and R. A. Fouchier, *N. Engl. J. Med.*, 2012, **367**, 1814–1820.
 - 21 M. Owusu, A. Annan, V. M. Corman, R. Larbi, P. Anti, J. F. Drexler, O. Agbenyega, Y. Adu-Sarkodie and C. Drosten, *PLoS One*, 2014, **9**, e99782.
 - 22 R. Dijkman, M. F. Jebbink, E. Gaunt, J. W. Rossen, K. E. Templeton, T. W. Kuijpers and L. van der Hoek, *J. Clin. Virol.*, 2012, **53**, 135–139.
 - 23 N. Friedman, H. Alter, M. Hindiyeh, E. Mendelson, Y. Shemer Avni and M. Mandelboim, *Viruses*, 2018, **10**, 515.
 - 24 A. Jean, C. Quach, A. Yung and M. Semret, *Pediatr. Infect. Dis. J.*, 2013, **32**, 325–329.
 - 25 I. M. Mackay, K. E. Arden, D. J. Speicher, N. T. O'Neil, P. K. McErlean, R. M. Greer, M. D. Nissen and T. P. Sloots, *Viruses*, 2012, **4**, 637–653.
 - 26 I. Heimdal, N. Moe, S. Krokstad, A. Christensen, L. H. Skanke, S. A. Nordbø and H. Døllner, *J. Infect. Dis.*, 2019, **219**, 1198–1206.
 - 27 A. W. Edridge, J. Kaczorowska, A. C. Hoste, M. Bakker, M. Klein, K. Loens, M. F. Jebbink, A. Matser, C. M. Kinsella and P. Rueda, *Nat. Med.*, 2020, 1–3.
 - 28 MERS situation update, World Health Organization, 2020.
 - 29 K. Kim, T. Tandi, J. W. Choi, J. Moon and M. Kim, *J. Hosp. Infect.*, 2017, **95**, 207–213.
 - 30 A. Assiri, A. McGeer, T. M. Perl, C. S. Price, A. A. Al Rabeeah, D. A. Cummings, Z. N. Alabdullatif, M. Assad, A. Almulhim and H. Makhdoom, *N. Engl. J. Med.*, 2013, **369**, 407–416.
 - 31 C.-M. Chu, V. C. Cheng, I. F. Hung, K.-S. Chan, B. S. Tang, T. H. Tsang, K.-H. Chan and K.-Y. Yuen, *Emerging Infect. Dis.*, 2005, **11**, 1882.
 - 32 Y.-H. Hsieh, C.-C. King, C. W. Chen, M.-S. Ho, S.-B. Hsu and Y.-C. Wu, *J. Theor. Biol.*, 2007, **244**, 729–736.
 - 33 S. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad and M. Lipsitch, *Science*, 2020, **368**, 860–868.
 - 34 F. Mauvais-Jarvis, *Diabetes*, 2020, **69**, 1857–1863.
 - 35 K. Kragholm, M. P. Andersen, T. A. Gerds, J. H. Butt, L. Østergaard, C. Polcwiartek, M. Phelps, C. Andersson, G. H. Gislason and C. Torp-Pedersen, *Clin. Infect. Dis.*, 2020, ciaa924.
 - 36 L. Shafique, A. Ihsan and Q. Liu, *Pathogens*, 2020, **9**, 240.
 - 37 W. Liu, L. Liu, G. Kou, Y. Zheng, Y. Ding, W. Ni, Q. Wang, L. Tan, W. Wu and S. Tang, *J. Clin. Microbiol.*, 2020, **58**, e00461-20.
 - 38 Q. Ye, A. M. West, S. Silletti and K. D. Corbett, *bioRxiv*, 2020, DOI: 10.1101/2020.05.17.100685.
 - 39 J. Van Elslande, B. Decru, S. Jonckheere, E. Van Wijngaerden, E. Houben, P. Vandecandelaere, C. Indevuyt, M. Depypere, S. Desmet and E. André, *Clin. Microbiol. Infect.*, 2020, **26**, 1557. e1551–1557. e1557.
 - 40 P. D. Burbelo, F. X. Riedo, C. Morishima, S. Rawlings, D. Smith, S. Das, J. R. Strich, D. S. Chertow, R. T. Davey Jr and J. I. Cohen, *J. Infect. Dis.*, 2020, **222**, 206–213.
 - 41 A. Hachim, N. Kavian, C. A. Cohen, A. W. Chin, D. K. Chu, C. K. Mok, O. T. Tsang, Y. C. Yeung, R. A. Perera and L. L. Poon, *Nat. Immunol.*, 2020, **21**, 1293–1301.
 - 42 A. K. Azkur, M. Akdis, D. Azkur, M. Sokolowska, W. van de Veen, M. C. Brügggen, L. O'Mahony, Y. Gao, K. Nadeau and C. A. Akdis, *Allergy*, 2020, **75**, 1564–1581.
 - 43 C. Yi, X. Sun, J. Ye, L. Ding, M. Liu, Z. Yang, X. Lu, Y. Zhang, L. Ma and W. Gu, *Cell. Mol. Immunol.*, 2020, 1–10.
 - 44 P. Forster, L. Forster, C. Renfrew and M. Forster, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 9241–9243.
 - 45 S. Ozono, Y. Zhang, H. Ode, T. S. Tan, K. Imai, K. Miyoshi, S. Kishigami, T. Ueno, Y. Iwatani, T. Suzuki and K. Tokunaga, *Nat. Commun.*, 2021, **12**, 848.

- 46 T. Koyama, D. Platt and L. Parida, *Bull. W. H. O.*, 2020, **98**, 495.
- 47 S. Isabel, L. Graña-Miraglia and J. M. Gutierrez, *et al.*, *Sci. Rep.*, 2020, **10**, 14031.
- 48 B. Korber, W. M. Fischer, S. Gnanakaran, H. Yoon, J. Theiler, W. Abfalterer, N. Hengartner, E. E. Giorgi, T. Bhattacharya and B. Foley, *Cell*, 2020, **182**(812-827), e819.
- 49 M. Becerra-Flores and T. Cardozo, *Int. J. Clin. Pract.*, 2020, e13525.
- 50 D. Mercatelli and F. M. Giorgi, *Front. Microbiol.*, 2020, **11**, 1800.
- 51 Q. Guan, M. Sadykov, S. Mfarrej, S. Hala, R. Naeem, R. Nugmanova, A. Al-Omari, S. Salih, A. Al Mutair and M. J. Carr, *Int. J. Infect. Dis.*, 2020, **100**, 216–223.
- 52 J. Van Elslande, P. Vermeersch, K. Vandervoort, T. Wawina-Bokalanga, B. Vanmechelen, E. Wollants, L. Laenen, E. André, M. Van Ranst, K. Lagrou and P. Maes, *Clin. Infect. Dis.*, 2021, **73**, 354–356.
- 53 K. K.-W. To, I. F.-N. Hung, J. D. Ip, A. W.-H. Chu, W.-M. Chan, A. R. Tam, C. H.-Y. Fong, S. Yuan, H.-W. Tsoi and A. C.-K. Ng, *Clin. Infect. Dis.*, 2020, ciaa1275.
- 54 R. L. Tillett, J. R. Sevinsky, P. D. Hartley, H. Kerwin, N. Crawford, A. Gorzalski, C. Laverdure, S. C. Verma, C. C. Rossetto and D. Jackson, *Lancet Infect. Dis.*, 2020, **21**, 52–58.
- 55 V. Gupta, R. C. Bhojar, A. Jain, S. Srivastava, R. Upadhayay, M. Imran, B. Jolly, D. Sharma, P. Sehgal and G. Ranjan, *Clin. Infect. Dis.*, 2020, ciaa1451.
- 56 J. D. Goldman, K. Wang, K. Röltgen, S. C. A. Nielsen, J. C. Roach, S. N. Naccache, F. Yang, O. F. Wirz, K. E. Yost, J.-Y. Lee, K. Chun, T. Wrin, C. J. Petropoulos, I. Lee, S. Fallen, P. M. Manner, J. A. Wallick, H. A. Algren, K. M. Murray, Y. Su, J. Hadlock, J. Jeharajah, W. R. Berrington, G. P. Pappas, S. T. Nyatsatsang, A. L. Greninger, A. T. Satpathy, J. S. Pauk, S. D. Boyd and J. R. Heath, *medRxiv*, 2020, DOI: 10.1101/2020.09.22.20192443.
- 57 B. Prado-Vivar, M. Becerra-Wong, J. J. Guadalupe, S. Marquez, B. Gutierrez, P. Rojas-Silva, M. Grunauer, G. Trueba, V. Barragan and P. Cardenas, *SSRN*, 2020, DOI: 10.2139/ssrn.3686174.
- 58 E. Hamed, S. Sedeeq, A. S. Alnuaimi, M. Syed, M. A. ElHamid, B. Alemrayat, A. Mukhtar, A. AlFehaidi and H. A/Qotba, *J. Infect.*, 2021, **82**, 84–123.
- 59 A. Gómez-Carballa, X. Bello, J. Pardo-Seco, F. Martín-Torres and A. Salas, *Genome Res.*, 2020, **30**, 1434–1448.
- 60 K. Pyrc, R. Dijkman, L. Deng, M. F. Jebbink, H. A. Ross, B. Berkhout and L. Van der Hoek, *J. Mol. Biol.*, 2006, **364**, 964–973.
- 61 H. Hofmann, K. Pyrc, L. Van Der Hoek, M. Geier, B. Berkhout and S. Pöhlmann, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 7988–7993.
- 62 Q. Shen, X. Xiao, A. Aierken, W. Yue, X. Wu, M. Liao and J. Hua, *J. Cell. Mol. Med.*, 2020, **24**, 9472–9477.
- 63 X. Zou, K. Chen, J. Zou, P. Han, J. Hao and Z. Han, *Front. Med.*, 2020, 1–8.
- 64 D. S. Dimitrov, *Cell*, 2003, **115**, 652–653.
- 65 M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.-H. Wu and A. Nitsche, *Cell*, 2020, **181**, 271–280.
- 66 R. Yan, Y. Zhang, Y. Li, L. Xia, Y. Guo and Q. Zhou, *Science*, 2020, **367**, 1444–1448.
- 67 D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham and J. S. McLellan, *Science*, 2020, **367**, 1260–1263.
- 68 E. S. Winkler, A. L. Bailey, N. M. Kafai, S. Nair, B. T. McCune, J. Yu, J. M. Fox, R. E. Chen, J. T. Earnest and S. P. Keeler, *Nat. Immunol.*, 2020, 1–9.
- 69 P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li and C.-L. Huang, *Nature*, 2020, **579**, 270–273.
- 70 J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang and L. Zhang, *Nature*, 2020, **581**, 215–220.
- 71 A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire and D. Veesele, *Cell*, 2020, **181**, 281–292.
- 72 M. Hussain, N. Jabeen, F. Raza, S. Shabbir, A. A. Baig, A. Amanullah and B. Aziz, *J. Med. Virol.*, 2020, **92**, 1580–1586.
- 73 K. Wang, W. Chen and Z. Zhang, *et al.*, *Signal Transduction Targeted Ther.*, 2020, **5**, 283.
- 74 H. Ulrich and M. M. Pillat, *Stem Cell Rev. Rep.*, 2020, 1–7.
- 75 B. Ahmetaj-Shala, R. Vaja, S. S. Atanur, P. M. George, N. S. Kirkby and J. A. Mitchell, *JACC: Basic to Translational Science*, 2020, **5**, 1111–1123.
- 76 C. Liu and D. Zhu, *Med. Drug Discovery*, 2020, 100056.
- 77 A. O. Sehirli, S. Sayiner and N. Serakinci, *Mol. Biol. Rep.*, 2020, 1–5.
- 78 H. Bian, Z.-H. Zheng, D. Wei, Z. Zhang, W.-Z. Kang, C.-Q. Hao, K. Dong, W. Kang, J.-L. Xia, J.-L. Miao, R.-H. Xie, B. Wang, X.-X. Sun, X.-M. Yang, P. Lin, J.-J. Geng, K. Wang, H.-Y. Cui, K. Zhang, X.-C. Chen, H. Tang, H. Du, N. Yao, S.-S. Liu, L.-N. Liu, Z. Zhang, Z.-W. Gao, G. Nan, Q.-Y. Wang, J.-Q. Lian, Z.-N. Chen and P. Zhumed, *Rxiv*, 2020, DOI: 10.1101/2020.03.21.20040691.
- 79 U. Radzikowska, M. Ding, G. Tan, D. Zhakparov, Y. Peng, P. Wawrzyniak, M. Wang, S. Li, H. Morita and C. Altunbulakli, *Allergy*, 2020, **75**, 2828–2844.
- 80 J. Shilts, T. W. M. Crozier, E. J. D. Greenwood, P. J. Lehner and G. J. Wright, *Sci. Rep.*, 2021, **11**, 143.
- 81 G. Lu, Y. Hu, Q. Wang, J. Qi, F. Gao, Y. Li, Y. Zhang, W. Zhang, Y. Yuan and J. Bao, *Nature*, 2013, **500**, 227–231.
- 82 V. S. Raj, H. Mou, S. L. Smits, D. H. Dekkers, M. A. Müller, R. Dijkman, D. Muth, J. A. Demmers, A. Zaki and R. A. Fouchier, *Nature*, 2013, **495**, 251–254.
- 83 N. Vankadari and J. A. Wilce, *Emerging Microbes Infect.*, 2020, **9**, 601–604.
- 84 H. Li, Y. Wang, M. Ji, F. Pei, Q. Zhao, Y. Zhou, Y. Hong, S. Han, J. Wang and Q. Wang, *Front. Cell Dev. Biol.*, 2020, **8**, 618.
- 85 M. Klompas, M. A. Baker and C. Rhee, *JAMA*, 2020, **324**, 441–442.
- 86 R. Sommerstein, C. A. Fux, D. Vuichard-Gysin, M. Abbas, J. Marschall, C. Balmelli, N. Troillet, S. Harbarth, M. Schlegel and A. Widmer, *Antimicrob. Resist. Infect. Contr.*, 2020, **9**, 1–8.

- 87 F. Yang, A. A. Pahlavan, S. Mendez, M. Abkarian and H. A. Stone, *Physical Review Fluids*, 2020, **5**, 122501.
- 88 S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Coupland, C. Whittaker, H. Zhu, T. Berah and J. W. Eaton, *Nature*, 2020, **584**, 257–261.
- 89 V. Stadnytskyi, C. E. Bax, A. Bax and P. Anfinrud, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 11875–11877.
- 90 S. Shao, D. Zhou, R. He, J. Li, S. Zou, K. Mallery, S. Kumar, S. Yang and J. Hong, *J. Aerosol Sci.*, 2020, **151**, 105661.
- 91 D. Mürbe, M. Fleischer, J. Lange, H. Rotheudt and M. Kriegel, *OSF Preprints*, 2020, DOI: 10.31219/osf.io/znjeh.
- 92 M. Alsved, A. Matamis, R. Bohlin, M. Richter, P.-E. Bengtsson, C.-J. Fraenkel, P. Medstrand and J. Löndahl, *Aerosol Sci. Technol.*, 2020, **54**, 1245–1248.
- 93 A. Endo, S. Abbott, A. J. Kucharski and S. Funk, *Wellcome Open Res.*, 2020, **5**, 67.
- 94 A. Heinzerling, P. M. J. Stuckey, T. Scheuer, K. Xu, K. M. Perkins, H. Resseger, S. Magill, J. R. Verani, S. Jain and M. Acosta, *Morb. Mortal. Wkly. Rep.*, 2020, **69**, 472–476.
- 95 L. Morawska and J. Cao, *Environ. Int.*, 2020, 105730.
- 96 L. Morawska and D. K. Milton, *Clin. Infect. Dis.*, 2020, **71**, 2311–2313.
- 97 A. Heinzerling, P. M. J. Stuckey, T. Scheuer, K. Xu, K. M. Perkins, H. Resseger, S. Magill, J. R. Verani, S. Jain and M. Acosta, *Morb. Mortal. Wkly. Rep.*, 2020, **69**, 472–476.
- 98 D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. Ipekci, G. Salanti and N. Low, *PLoS Med.*, 2020, **17**, e1003346.
- 99 W. Sungnak, N. Huang, C. Bécavin, M. Berg, R. Queen, M. Litvinukova, C. Talavera-López, H. Maatz, D. Reichart and F. Sampaziotis, *Nat. Med.*, 2020, **26**, 681–687.
- 100 C. Wu and M. Zheng, *medRxiv*, 2020, DOI: 10.1101/2020.02.11.20022228.
- 101 S. N. Mueller and B. T. Rouse, *Clin. Immunol.*, 2008, 421.
- 102 S. L. Klein and S. Huber, *Sex hormones and immunity to infection*, Springer, 2010, pp. 93–122.
- 103 S. L. Klein, *BioEssays*, 2012, **34**, 1050–1059.
- 104 Z. Gao, Y. Xu, Y. Guo, D. Xu, L. Zhang, X. Wang, C. Sun, S. Qiu and K. Ma, *Infect., Genet. Evol.*, 2020, 104494.
- 105 H.-w. Jiang, H.-n. Zhang, Q.-f. Meng, J. Xie, Y. Li, H. Chen, Y.-x. Zheng, X.-n. Wang, H. Qi and J. Zhang, *Cell. Mol. Immunol.*, 2020, **17**, 998–1000.
- 106 R. Zhou, K. K.-W. To, Y.-C. Wong, L. Liu, B. Zhou, X. Li, H. Huang, Y. Mo, T.-Y. Luk and T. T.-K. Lau, *Immunity*, 2020, **53**, 864–877.
- 107 A. Bouayad, *Rev. Med. Virol.*, 2020, e2135.
- 108 Q.-X. Long, B.-Z. Liu, H.-J. Deng, G.-C. Wu, K. Deng, Y.-K. Chen, P. Liao, J.-F. Qiu, Y. Lin and X.-F. Cai, *Nat. Med.*, 2020, 1–4.
- 109 J. Prévost, R. Gasser, G. Beaudoin-Bussièrès, J. Richard, R. Duerr, A. Laumaea, S. P. Anand, G. Goyette, M. Benlarbi and S. Ding, *Cell Rep. Med.*, 2020, **1**, 100126.
- 110 J. Seow, C. Graham and B. Merrick, *et al.*, *Nat. Microbiol.*, 2020, **5**, 1598–1607.
- 111 B. Lou, T.-D. Li, S.-F. Zheng, Y.-Y. Su, Z.-Y. Li, W. Liu, F. Yu, S.-X. Ge, Q.-D. Zou and Q. Yuan, *Eur. Respir. J.*, 2020, 2000763.
- 112 N. M. A. Okba, M. A. Müller, W. Li, C. Wang, C. H. GeurtsvanKessel, V. M. Corman, M. M. Lamers, R. S. Sikkema, E. de Bruin, F. D. Chandler, Y. Yazdanpanah, Q. Le Hingrat, D. Descamps, N. Houhou-Fidouh, C. B. E. M. Reusken, B.-J. Bosch, C. Drosten, M. P. G. Koopmans and B. L. Haagmans, *medRxiv*, 2020, DOI: 10.1101/2020.2003.2018.20038059.
- 113 J. Qu, C. Wu, X. Li, G. Zhang, Z. Jiang, X. Li, Q. Zhu and L. Liu, *Clin. Infect. Dis.*, 2020, **71**, 2255–2258.
- 114 P. K. Kiyuka, C. N. Agoti, P. K. Munywoki, R. Njeru, A. Bett, J. R. Otieno, G. P. Otieno, E. Kamau, T. G. Clark and L. van der Hoek, *J. Infect. Dis.*, 2018, **217**, 1728–1739.
- 115 P. Kellam and W. Barclay, *J. Gen. Virol.*, 2020, **101**, 791–797.
- 116 J.-W. Song, C. Zhang, X. Fan, F.-P. Meng, Z. Xu, P. Xia, W.-J. Cao, T. Yang, X.-P. Dai and S.-Y. Wang, *Nat. Commun.*, 2020, **11**, 1–10.
- 117 W. Liu, A. Fontanet, P.-H. Zhang, L. Zhan, Z.-T. Xin, L. Baril, F. Tang, H. Lv and W.-C. Cao, *J. Infect. Dis.*, 2006, **193**, 792–795.
- 118 A. Grifoni, D. Weiskopf, S. I. Ramirez, J. Mateus, J. M. Dan, C. R. Moderbacher, S. A. Rawlings, A. Sutherland, L. Premkumar and R. S. Jardi, *Cell*, 2020, **181**, 1489–1501.
- 119 J. Braun, L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M. Dingeldey, B. Kruse and F. Fauchere, *Nature*, 2020, 1–5.
- 120 H. Ward, G. Cooke, C. Atchison, M. Whitaker, J. Elliott, M. Moshe, J. C. Brown, B. Flower, A. Daunt, K. Ainslie, D. Ashby, C. Donnelly, S. Riley, A. Darzi, W. Barclay, P. Elliott and for the REACT study team, *medRxiv*, 2020, DOI: 10.1101/2020.10.26.20219725.
- 121 A. S. Iyer, F. K. Jones, A. Nodoushani, M. Kelly, M. Becker, D. Slater, R. Mills, E. Teng, M. Kamruzzaman and W. F. Garcia-Beltran, *Sci. Immunol.*, 2020, **5**, eabe0367.
- 122 M. M. Patel, N. J. Thornburg, W. B. Stubblefield, H. K. Talbot, M. M. Coughlin, L. R. Feldstein and W. H. Self, *JAMA*, 2020, **324**, 1781–1782.
- 123 W. H. Self, M. W. Tenforde and W. B. Stubblefield, *et al.*, *Morb. Mortal. Wkly. Rep.*, 2020, **69**, 1762–1766.
- 124 G. Moncunill, A. Mayor, R. Santano, A. Jiménez, M. Vidal, M. Tortajada, S. Sanz, S. Méndez, A. Llupià and R. Aguilar, *J. Infect. Dis.*, 2021, **223**, 62–71.
- 125 B. Isho, K. T. Abe, M. Zuo, A. J. Jamal, B. Rathod, J. H. Wang, Z. Li, G. Chao, O. L. Rojas and Y. M. Bang, *Sci. Immunol.*, 2020, **5**, eabe5511.
- 126 L. B. Rodda, J. Netland, L. Shehata, K. B. Pruner, P. A. Morawski, C. D. Thouvenel, K. K. Takehara, J. Eggenberger, E. A. Hemann and H. R. Waterman, *Cell*, 2020, **184**, 169–183.
- 127 J. M. Dan, J. Mateus and Y. Kato, *et al.*, *Science*, 2021, **371**, eabf4063.
- 128 T. L. Dao and P. Gautret, *Eur. J. Clin. Microbiol. Infect. Dis.*, 2020, 1–13.
- 129 Q. Mei, J. Li, R. Du, X. Yuan, M. Li and J. Li, *Lancet Infect. Dis.*, 2020, **20**, 1004–1005.
- 130 N. Baumgarth, J. Nikolich-Zugich, F. E.-H. Lee and D. Bhattacharya, *J. Immunol.*, 2020, **205**, 2342–2350.
- 131 P. Habibzadeh, M. M. Sajadi, A. Emami, M. H. Karimi, M. Yadollahie, M. Kucheki, S. Akbarpoor and F. Habibzadeh, *Biochem. Med.*, 2020, **30**, 355–356.

- 132 K. Callow, H. Parry, M. Sergeant and D. Tyrrell, *Epidemiol. Infect.*, 1990, **105**, 435–446.
- 133 X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong and Y. Yang, *Science*, 2020, **369**, 650–655.
- 134 Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann and E. Michailidis, *eLife*, 2020, **9**, e61312.
- 135 S. Tomassini, D. Kotecha, P. W. Bird, A. Folwell, S. Biju and J. W. Tang, *J. Infect.*, 2020, **82**, 282–327.
- 136 F. Amanat and F. Krammer, *Immunity*, 2020, **52**, 583–589.
- 137 F. Krammer, *Nature*, 2020, **586**, 516–527.
- 138 T. T. Le, Z. Andreadakis, A. Kumar, R. G. Roman, S. Tollesfsen, M. Saville and S. Mayhew, *Nat. Rev. Drug Discovery*, 2020, **19**, 305–306.
- 139 M. Jeyanathan, S. Afkhami, F. Smaill, M. S. Miller, B. D. Lichty and Z. Xing, *Nat. Rev. Immunol.*, 2020, 1–18.
- 140 S. P. Kaur and V. Gupta, *Virus Res.*, 2020, 198114.
- 141 M. D. Shin, S. Shukla, Y. H. Chung, V. Beiss, S. K. Chan, O. A. Ortega-Rivera, D. M. Wirth, A. Chen, M. Sack and J. K. Pokorski, *Nat. Nanotechnol.*, 2020, **15**, 646–655.
- 142 J. Routh, *National Institutes of Health press release*, 2020, <https://www.nih.gov/news-events/news-releases/fourth-large-scale-covid-19-vaccine-trial-begins-united-states>.
- 143 E. E. Walsh, R. Frenck, A. R. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, M. J. Mulligan and R. Bailey, *et al.*, *medRxiv*, 2020, DOI: 10.1101/2020.08.17.20176651.
- 144 J. Bowden, HHS secretary: FDA will move ‘as quickly as possible’ on Moderna, Pfizer vaccines, *The Hill*, 2020, <https://thehill.com/policy/healthcare/public-global-health/526113-hhs-secretary-fda-moderna-pfizer-vaccines-coronavirus>.
- 145 GVN Statement on Pfizer and BioNTech Data from COVID-19 Vaccine Study, Global Virus Network, 2020.
- 146 J. Palca, *Moderna’s COVID-19 Vaccine Shines In Clinical Trial*, National Public Radio, NPR, 2020.
- 147 X. Yuan, C. Yang, Q. He, J. Chen, D. Yu, J. Li, S. Zhai, Z. Qin, K. Du, Z. Chu and P. Qin, *ACS Infect. Dis.*, 2020, **6**, 1998–2016.
- 148 E. Sheikhzadeh, S. Eissa, A. Ismail and M. Zourob, *Talanta*, 2020, **220**, 121392.
- 149 L. J. Carter, L. V. Garner, J. W. Smoot, Y. Li, Q. Zhou, C. J. Saveson, J. M. Sasso, A. C. Gregg, D. J. Soares, T. R. Beskid, S. R. Jervey and C. Liu, *ACS Cent. Sci.*, 2020, **6**, 591–605.
- 150 O. Vandenberg, D. Martiny, O. Rochas, A. van Belkum and Z. Kozlakidis, *Nat. Rev. Microbiol.*, 2020, **19**, 171–183.
- 151 M. Venter and K. Richter, *J. Clin. Pathol.*, 2020, **73**, 370.
- 152 M. L. Wong and J. F. Medrano, *Biotechniques*, 2005, **39**, 75–85.
- 153 I. M. Mackay, K. E. Arden and A. Nitsche, *Nucleic Acids Res.*, 2002, **30**, 1292–1305.
- 154 Y. Yan, L. Chang, W. Luo, J. Liu, F. Guo and L. Wang, *J. Mol. Diagn.*, 2021, **23**, 300–309.
- 155 X. He, E. H. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan and X. Tan, *Nat. Med.*, 2020, **26**, 672–675.
- 156 Y.-H. Xing, W. Ni, Q. Wu, W.-J. Li, G.-J. Li, W.-D. Wang, J.-N. Tong, X.-F. Song, G. W.-K. Wong and Q.-S. Xing, *J. Microbiol., Immunol. Infect.*, 2020, **53**, 473–480.
- 157 Y. Sohn, S. J. Jeong, W. S. Chung, J. H. Hyun, Y. J. Baek, Y. Cho, J. H. Kim, J. Y. Ahn, J. Y. Choi and J.-S. Yeom, *J. Clin. Med.*, 2020, **9**, 2924.
- 158 A. Afzal, *J. Adv. Res.*, 2020, 149–159.
- 159 J. B. Mahony, G. Blackhouse, J. Babwah, M. Smieja, S. Buracond, S. Chong, W. Ciccotelli, T. O’Shea, D. Alnakhli and M. Griffiths-Turner, *J. Clin. Microbiol.*, 2009, **47**, 2812–2817.
- 160 K. Ramdas, A. Darzi and S. Jain, *Nat. Med.*, 2020, 1–2.
- 161 C. Sheridan, *Nat. Biotechnol.*, 2020, **38**, 515–518.
- 162 D. Thompson and Y. Lei, *Sens. Actuator Rep.*, 2020, **2**, 100017.
- 163 A. Gansen, A. M. Herrick, I. K. Dimov, L. P. Lee and D. T. Chiu, *Lab Chip*, 2012, **12**, 2247–2254.
- 164 V. L. Dao Thi, K. Herbst, K. Boerner, M. Meurer, L. P. M. Kremer, D. Kirrmaier, A. Freistaedter, D. Papagiannidis, C. Galmozzi, M. L. Stanifer, S. Boulant, S. Klein, P. Chlanda, D. Khalid, I. Barreto Miranda, P. Schnitzler, H.-G. Kräusslich, M. Knop and S. Anders, *Sci. Transl. Med.*, 2020, **12**, eabc7075.
- 165 J. J. Schellenberg, M. Ormond and Y. Keynan, *J. Clin. Virol.*, 2021, **136**, 104764.
- 166 R. Pelton, *TrAC, Trends Anal. Chem.*, 2009, **28**, 925–942.
- 167 P. Kumar, Y. S. Malik, B. Ganesh, S. Rahangdale, S. Saurabh, S. Natesan, A. Srivastava, K. Sharun, M. I. Yattoo, R. Tiwari, R. K. Singh and K. Dhama, *Front. Cell. Infect. Microbiol.*, 2020, **10**, 639.
- 168 J. S. Gootenberg, O. O. Abudayyeh, M. J. Kellner, J. Joung, J. J. Collins and F. Zhang, *Science*, 2018, **360**, 439.
- 169 J. Joung, A. Ladha and M. Saito, *et al.*, *N. Engl. J. Med.*, 2020, **383**, 1492–1494.
- 170 L. Guo, X. Sun, X. Wang, C. Liang, H. Jiang, Q. Gao, M. Dai, B. Qu, S. Fang, Y. Mao, Y. Chen, G. Feng, Q. Gu, R. R. Wang, Q. Zhou and W. Li, *Cell Discovery*, 2020, **6**, 34.
- 171 A. K. Kaushik, J. S. Dhau, H. Gohel, Y. K. Mishra, B. Kateb, N.-Y. Kim and D. Y. Goswami, *ACS Appl. Bio Mater.*, 2020, **3**, 7306–7325.
- 172 H. Zhao, F. Liu, W. Xie, T.-C. Zhou, J. OuYang, L. Jin, H. Li, C.-Y. Zhao, L. Zhang, J. Wei, Y.-P. Zhang and C.-P. Li, *Sens. Actuators, B*, 2021, **327**, 128899.
- 173 A. Ahmadivand, B. Gerislioglu, Z. Ramezani, A. Kaushik, P. Manickam and S. A. Ghoreishi, *Biosens. Bioelectron.*, 2021, **177**, 112971.
- 174 G. Qiu, Z. Gai, Y. Tao, J. Schmitt, G. A. Kullak-Ublick and J. Wang, *ACS Nano*, 2020, **14**, 5268–5277.
- 175 B. O’Farrell, in *Lateral Flow Immunoassay*, ed. R. Wong and H. Tse, Humana Press, Totowa, NJ, 2009, pp. 1–33, DOI: 10.1007/978-1-59745-240-3_1.
- 176 S. Eustis and M. A. El-Sayed, *Chem. Soc. Rev.*, 2006, **35**, 209–217.
- 177 D. Hristov, A. J. Pimentel, G. Ujjialele and K. Hamad-Schifferli, *ACS Appl. Mater. Interfaces*, 2020, **12**, 34620–34629.

- 178 D. R. Hristov, C. Rodriguez-Quijada, J. Gomez-Marquez and K. Hamad-Schifferli, *Sensors*, 2019, **19**, 554.
- 179 S. Rosen, in *Lateral Flow Immunoassay*, ed. R. Wong and H. Tse, Humana Press, Totowa, NJ, 2009, pp. 1–15, DOI: 10.1007/978-1-59745-240-3_2.
- 180 H. Kim, D.-R. Chung and M. Kang, *Analyst*, 2019, **144**, 2460–2466.
- 181 N. P. Pai, C. Vadnais, C. Denkinger, N. Engel and M. Pai, *PLoS Med.*, 2012, **9**, e1001306.
- 182 F. M. Liotti, G. Menchinelli, E. Lalle, I. Palucci, S. Marchetti, F. Colavita, M. La Sorda, G. Sberna, L. Bordi, M. Sanguinetti, P. Cattani, M. R. Capobianchi and B. Posteraro, *Clin. Microbiol. Infect.*, 2021, **27**, 487–488.
- 183 S. Lambert-Niclot, A. Cuffel, S. Le Pape, C. Vauloup-Fellous, L. Morand-Joubert, A.-M. Roque-Afonso, J. Le Goff and C. Delaugerre, *J. Clin. Microbiol.*, 2020, **58**, e00977–e00920.
- 184 C. Rodriguez-Quijada, J. Gomez-Marquez and K. Hamad-Schifferli, *ACS Nano*, 2020, **14**, 6626–6635.
- 185 C.-W. Yen, H. de Puig, J. Tam, J. Gómez-Márquez, I. Bosch, K. Hamad-Schifferli and L. Gehrke, *Lab Chip*, 2015, **15**, 1638–1641.
- 186 D. Hristov, H. Rijal, G.-M. Jose and K. Hamad, *ChemRxiv*, 2020, DOI: 10.26434/chemrxiv.13476738.v1.
- 187 D. Cate, H. Hsieh, V. Glukhova, J. D. Bishop, H. G. Hermansky, B. Barrios-Lopez, B. D. Grant, C. E. Anderson, E. Spencer, S. Kuhn, R. Gallagher, R. Rivera, C. Bennett, S. A. Byrnes, J. T. Connelly, P. K. Dewan, D. S. Boyle, B. H. Weigl and K. P. Nichols, *ChemRxiv*, 2020, DOI: 10.26434/chemrxiv.12709538.v1.
- 188 D. Hristov, H. Rijal, J. Gomez-Marquez and K. Hamad-Schifferli, *Anal. Chem.*, 2021, **93**, 7825–7832.
- 189 Y. Hirotsu, M. Maejima, M. Shibusawa, Y. Nagakubo, K. Hosaka, K. Amemiya, H. Sueki, M. Hayakawa, H. Mochizuki, T. Tsutsui, Y. Kakizaki, Y. Miyashita, S. Yagi, S. Kojima and M. Omata, *Int. J. Infect. Dis.*, 2020, **99**, 397–402.
- 190 L. Russo, M. Sanchez-Purra, C. Rodríguez-Quijada, B. M. Leonardo, V. Puentes and K. Hamad-Schifferli, *Nanoscale*, 2019, **11**, 10819–10827.
- 191 M. Sánchez-Purrà, M. Carré Camps, H. de Puig Guixé, I. Bosch, L. Gehrke and K. Hamad-Schifferli, *ACS Infect. Dis.*, 2017, **3**, 767–776.
- 192 M. Sanchez-Purra, B. Roig-Solvas, C. Rodríguez-Quijada, B. Leonardo and K. Hamad-Schifferli, *ACS Omega*, 2018, **3**, 10733–10742.
- 193 E. Juntunen, T. Myrskyläinen, T. Salminen, T. Soukka and K. Pettersson, *Anal. Biochem.*, 2012, **428**, 31–38.
- 194 J. Liu, B. Du, P. Zhang, M. Haleyrigirisetty, J. Zhao, V. Ragupathy, S. Lee, D. L. DeVoe and I. K. Hewlett, *Biosens. Bioelectron.*, 2014, **61**, 177–183.
- 195 G. Seo, G. Lee, M. J. Kim, S.-H. Baek, M. Choi, K. B. Ku, C.-S. Lee, S. Jun, D. Park, H. G. Kim, S.-J. Kim, J.-O. Lee, B. T. Kim, E. C. Park and S. I. Kim, *ACS Nano*, 2020, **14**, 5135–5142.
- 196 B. D. Ventura, M. Cennamo, A. Minopoli, R. Campanile, S. B. Censi, D. Terracciano, G. Portella and R. Velotta, *ACS Sens.*, 2020, **5**, 3043–3048.
- 197 K. T. C. Babak, Y. Moghadam and J. D. Posner, *Anal. Chem.*, 2015, **87**, 1009–1017.
- 198 Z. Qin, W. C. W. Chan, D. R. Boulware, T. Akkin, E. K. Butler and J. C. Bischof, *Angew. Chem., Int. Ed.*, 2012, **51**, 4358–4361.
- 199 D. W. Denning, A. Kilcoyne and C. Ucer, *Br. Dent. J.*, 2020, **229**, 521–524.
- 200 A. La Marca, M. Capuzzo, T. Paglia, L. Roli, T. Trenti and S. M. Nelson, *Reprod. Biomed. Online*, 2020, **41**, 483–499.
- 201 S. Kasetsirikul, M. Umer, N. Soda, K. R. Sreejith, M. J. A. Shiddiky and N.-T. Nguyen, *Analyst*, 2020, **145**, 7680–7686.
- 202 J. D. Whitman, J. Hiatt and C. T. Mowery, *et al.*, *Nat. Biotechnol.*, 2020, **38**, 1174–1183.
- 203 J. Van Elslande, E. Houben, M. Depypere, A. Brackenier, S. Desmet, E. André, M. Van Ranst, K. Lagrou and P. Vermeersch, *Clin. Microbiol. Infect.*, 2020, **26**, 1082–1087.
- 204 M. Tré-Hardy, A. Wilmet, I. Beukinga, J. Favresse, J.-M. Dogné, J. Douxfils and L. Blairon, *J. Med. Virol.*, 2021, **93**, 803–811.
- 205 M. Lisboa Bastos, G. Tavaziva, S. K. Abidi, J. R. Campbell, L.-P. Haraoui, J. C. Johnston, Z. Lan, S. Law, E. MacLean, A. Trajman, D. Menzies, A. Benedetti and F. Ahmad Khan, *BMJ*, 2020, **370**, m2516.
- 206 E. R. Adams, M. Ainsworth and R. Anand, *et al.*, *Wellcome Open Res.*, 2020, **5**, 139.
- 207 M. M. Serrano, D. N. Rodríguez, N. T. Palop, R. O. Arenas, M. M. Córdoba, M. D. O. Mochón and C. G. Cardona, *J. Clin. Virol.*, 2020, **129**, 104529.
- 208 H. Liu, E. Dai, R. Xiao, Z. Zhou, M. Zhang, Z. Bai, Y. Shao, K. Qi, J. Tu, C. Wang and S. Wang, *Sens. Actuators, B*, 2020, 129196.
- 209 Z. Chen, Z. Zhang, X. Zhai, Y. Li, L. Lin, H. Zhao, L. Bian, P. Li, L. Yu, Y. Wu and G. Lin, *Anal. Chem.*, 2020, **92**, 7226–7231.
- 210 G. E. Fridley, C. A. Holstein, S. B. Oza and P. Yager, *MRS Bull.*, 2013, **38**, 326–330.
- 211 E. Fu, B. Lutz, P. Kauffman and P. Yager, *Lab Chip*, 2010, **10**, 918–920.
- 212 C. Parolo, M. Medina-Sánchez, A. de la Escosura-Muñiz and A. Merkoçi, *Lab Chip*, 2013, **13**, 386–390.
- 213 P. Chun, in *Lateral Flow Immunoassay*, ed. R. Wong and H. Tse, Humana Press, Totowa, NJ, 2009, pp. 1–19, DOI: 10.1007/978-1-59745-240-3_5.
- 214 J. O. Tam, H. de Puig, C.-W. Yen, I. Bosch, J. Gómez-Márquez, C. Clavet, K. Hamad-Schifferli and L. Gehrke, *J. Immunoassay Immunochem.*, 2017, **38**, 355–377.
- 215 D. R. Hristov, H. Lopez, Y. Ortin, K. O'Sullivan, K. A. Dawson and D. F. Brougham, *Nanoscale*, 2021, **13**, 5344–5355.
- 216 H. de Puig, I. Bosch, M. Carre-Camps and K. Hamad-Schifferli, *Bioconjugate Chem.*, 2017, **28**, 230–238.
- 217 L. Soddu, D. N. Trinh, E. Dunne, D. Kenny, G. Bernardini, I. Kokalari, A. Marucco, M. P. Monopoli and I. Fenoglio, *Beilstein J. Nanotechnol.*, 2020, **11**, 550–567.
- 218 A. Salvati, A. S. Pitek, M. P. Monopoli, K. Prapainop, F. B. Bombelli, D. R. Hristov, P. M. Kelly, C. Åberg,

- E. Mahon and K. A. Dawson, *Nat. Nanotechnol.*, 2013, **8**, 137–143.
- 219 M. P. Monopoli, C. Åberg, A. Salvati and K. A. Dawson, *Nat. Nanotechnol.*, 2012, **7**, 779–786.
- 220 R. Cai and C. Chen, *Adv. Mater.*, 2019, **31**, 1805740.
- 221 F. Schaumburg, P. A. Kler and C. L. A. Berli, *Sens. Actuators, B*, 2018, **259**, 1099–1107.
- 222 Z. Allam, in *Surveying the Covid-19 Pandemic and its Implications*, ed. Z. Allam, Elsevier, 2020, pp. 71–79, DOI: 10.1016/B978-0-12-824313-8.00004-8.
- 223 M. A. Mujawar, H. Gohel, S. K. Bhardwaj, S. Srinivasan, N. Hickman and A. Kaushik, *Mater. Today Chem.*, 2020, **17**, 100306.
- 224 S. Jain, M. Nehra, R. Kumar, N. Dilbaghi, T. Hu, S. Kumar, A. Kaushik and C.-Z. Li, *Biosens. Bioelectron.*, 2021, **179**, 113074.
- 225 P. Paliwal, S. Sargolzaei, S. K. Bhardwaj, V. Bhardwaj, C. Dixit and A. Kaushik, *Frontiers in Nanotechnology*, 2020, **2**, 5.
- 226 I. O. Ogunkola, Y. A. Adebisi, U. F. Imo, G. O. Odey, E. Esu and D. E. Lucero-Prisno Iii, *Int. J. Health Plann. Manag.*, 2020, **35**, 1302–1305.
- 227 A. K. Giri and D. R. Rana, *Biosafety and Health*, 2020, **2**, 53–56.
- 228 J. Gomez-Marquez and K. Hamad-Schifferli, *Adv. Healthcare Mater.*, 2019, 1900184, DOI: 10.1002/adhm.201900184.
- 229 P. Ondo, Y. Kebede, M. M. Loembe, J. N. Bhiman, S. K. Tessema, A. Sow, A. A. Sall and J. Nkengasong, *Lancet Microbe*, 2020, **1**, e103–e104.
- 230 A. Olalekan, B. Iwalokun, O. M. Akinloye, O. Popoola, T. A. Samuel and O. Akinloye, *Afr. J. Lab. Med.*, 2020, **9**, a1255.
- 231 M. Peplow, *Chem. Eng. News*, 2020, **98**, 27.
- 232 J. Gomez-Marquez and K. Hamad-Schifferli, *Nat. Nanotechnol.*, 2020, **16**, 484–486.
- 233 C. Gortazar, L. A. Reperant and T. Kuiken, *et al.*, *PLoS Pathog.*, 2014, **10**, e1004129.
- 234 C. M. Saad-Roy, C. E. Wagner, R. E. Baker, S. E. Morris, J. Farrar, A. L. Graham, S. A. Levin, M. J. Mina, C. J. E. Metcalf and B. T. Grenfell, *Science*, 2020, **370**, 811.
- 235 F. G. Sandmann, N. G. Davies and A. Vassall, *et al.*, *Lancet Infect. Dis.*, 2021, **21**, 962–974.
- 236 H. C. Yalcin and A. Kaushik, *Emergent Mater.*, 2021, **4**, 1–2.